19 months ago

david 4.3k

@david_fe

Simplified Abstract

Objective: Halting and reversing glaucoma therapy-related ocular surface disease (GTR-OSD) will improve the success of long-term medical therapy, impacting millions of patients worldwide.

Methods: A single-centre, masked, prospective, placebo-controlled, crossover trial of:

• 41 well-controlled open-angle glaucoma subjects
  • with moderate to severe glaucoma therapy-related ocular surface disease (GTR-OSD)
  • on preserved latanoprost and dorzolamide/timolol fixed combination (DTFC) therapy

was conducted.

Results: Glaucoma therapy-related ocular surface disease (GTR-OSD) improved with preservative-free therapy.

Conclusions: Changing from preserved to PF glaucoma medications improves ocular surface health and IOP control. Topical cyclosporine 0.1% further reverses GTR-OSD.

• Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease-a randomized controlled trial - PubMed
• PMID: 37221362
• DOI: 10.1038/s41433-023-02578-w
• Eye (Lond)